What should the nurse tell a client reporting darker urine after starting carbidopa/levodopa therapy?

When a client reports darker urine after starting carbidopa/levodopa therapy, it is important to understand that this phenomenon can occur as a benign side effect of the medication. Carbidopa/levodopa, used primarily for managing symptoms of Parkinson's disease, can lead to changes in urine color due to the way the body metabolizes these medications.

The darker urine does not usually indicate a serious issue or toxicity but rather reflects the excretion of the medication and its metabolites. While it is crucial for patients to be aware of any significant changes in their health state, in this instance, informing the client about this occasional side effect helps to alleviate unnecessary concern. Encouraging a level of awareness about what to expect while on this treatment can empower the client and promote adherence to their medication regimen without panic or misunderstanding.

The other choices suggest actions that may not be necessary given that darker urine can be a common side effect, not requiring immediate medical intervention or excessive hydration unless symptoms worsen or additional issues arise.